Crossmark Global Holdings, Inc. Pacira Bio Sciences, Inc. Transaction History

Crossmark Global Holdings, Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$26.32 - $34.31 $14,054 - $18,321	-534 Reduced 4.42%	11,553 $390,000
Q3 2023 Nov 08, 2023	BUY	$30.68 - $40.09 $14,603 - $19,082	476 Added 4.1%	12,087 $380,000
Q2 2023 Jul 31, 2023	SELL	$36.12 - $47.5 $1,769 - $2,327	-49 Reduced 0.42%	11,611 $415,000
Q1 2023 May 12, 2023	BUY	$35.53 - $43.38 $49,884 - $60,905	1,404 Added 13.69%	11,660 $476,000
Q4 2022 Jan 19, 2023	BUY	$38.19 - $57.45 $22,684 - $34,125	594 Added 6.15%	10,256 $396,000
Q3 2022 Nov 01, 2022	SELL	$51.24 - $58.89 $9,786 - $11,247	-191 Reduced 1.94%	9,662 $514,000
Q2 2022 Jul 29, 2022	SELL	$51.49 - $81.64 $2,574 - $4,082	-50 Reduced 0.5%	9,853 $575,000
Q1 2022 May 11, 2022	BUY	$60.03 - $76.49 $317,138 - $404,096	5,283 Added 114.35%	9,903 $756,000
Q4 2021 Jan 10, 2022	SELL	$47.97 - $62.21 $268,152 - $347,753	-5,590 Reduced 54.75%	4,620 $278,000
Q3 2021 Oct 21, 2021	BUY	$54.64 - $61.3 $557,874 - $625,873	10,210 New	10,210 $572,000
Q3 2021 Oct 13, 2021	SELL	$54.64 - $61.3 $562,792 - $631,390	-10,300 Closed	0 $0
Q2 2021 Jul 21, 2021	SELL	$59.18 - $69.99 $10,060 - $11,898	-170 Reduced 1.62%	10,300 $625,000
Q1 2021 Apr 15, 2021	BUY	$59.31 - $78.82 $11,268 - $14,975	190 Added 1.85%	10,470 $734,000
Q4 2020 Jan 14, 2021	BUY	$50.47 - $66.26 $298,277 - $391,596	5,910 Added 135.24%	10,280 $615,000
Q3 2020 Oct 08, 2020	BUY	$51.97 - $63.0 $8,834 - $10,710	170 Added 4.05%	4,370 $263,000
Q2 2020 Aug 14, 2020	BUY	$30.8 - $52.47 $129,360 - $220,374	4,200 New	4,200 $220,000

263

50.4M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $892M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.